<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Trop. Dis</journal-id>
<journal-title>Frontiers in Tropical Diseases</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Trop. Dis</abbrev-journal-title>
<issn pub-type="epub">2673-7515</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fitd.2023.1108317</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Tropical Diseases</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabolomics for biomarker discovery in schistosomiasis: A systematic scoping review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Midzi</surname>
<given-names>Herald</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2109092"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vengesai</surname>
<given-names>Arthur</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1791407"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muleya</surname>
<given-names>Victor</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1719783"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kasambala</surname>
<given-names>Maritha</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2118421"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mduluza-Jokonya</surname>
<given-names>Tariro Lavender</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chipako</surname>
<given-names>Isaac</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Siamayuwa</surname>
<given-names>Clayton Edmore</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mutapi</surname>
<given-names>Francisca</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/170728"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Naicker</surname>
<given-names>Thajasvarie</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mduluza</surname>
<given-names>Takafira</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Biochemistry and Biotechnology, University of Zimbabwe</institution>, <addr-line>Harare</addr-line>, <country>Zimbabwe</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Doris Duke Medical Research Institute, College of Health Sciences, Optics &amp; Imaging, University of KwaZulu-Natal</institution>, <addr-line>KwaZulu-Natal, Durban</addr-line>, <country>South Africa</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Faculty of Medicine and Health Sciences, Department of Biochemistry, Midlands State University</institution>, <addr-line>Gweru</addr-line>, <country>Zimbabwe</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Biological Sciences and Ecology, University of Zimbabwe</institution>, <addr-line>Harare</addr-line>, <country>Zimbabwe</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Faculty of Medicine and Health Science, University of Zimbabwe</institution>, <addr-line>Harare</addr-line>, <country>Zimbabwe</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Pharmacology Department Aravas Pharmaceuticals Pvt LTD, Prospect Industrial Area</institution>, <addr-line>Harare</addr-line>, <country>Zimbabwe</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Ashworth Laboratories, Institute for Immunology and Infection Research and Centre for Immunity, Infection and Evolution, School of Biological Sciences, University of Edinburgh</institution>, <addr-line>Edinburgh</addr-line>, <country>Scotland</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Srinivasa P. S. Rao, Novartis Institute for Tropical Diseases, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Bartholomew N. Ondigo, Egerton University, Kenya; Alexandra Probst, Novartis Institute for Tropical Diseases, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Herald Midzi, <email xlink:href="mailto:midziherald@gmail.com">midziherald@gmail.com</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Neglected Tropical Diseases, a section of the journal Frontiers in Tropical Diseases</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>4</volume>
<elocation-id>1108317</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>01</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Midzi, Vengesai, Muleya, Kasambala, Mduluza-Jokonya, Chipako, Siamayuwa, Mutapi, Naicker and Mduluza</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Midzi, Vengesai, Muleya, Kasambala, Mduluza-Jokonya, Chipako, Siamayuwa, Mutapi, Naicker and Mduluza</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Metabolomic based approaches are essential tools in the discovery of unique biomarkers for infectious diseases <italic>via</italic> high-throughput global assessment of metabolites and metabolite pathway dysregulation. This in-turn allows the development of diagnostic tools and provision of therapeutics. In this review, we aimed to give an overview of metabolite biomarkers and metabolic pathway alterations during <italic>Schistosoma haematobium</italic> and <italic>Schistosoma mansoni</italic> infections.</p>
</sec>
<sec>
<title>Methods</title>
<p>We conducted the review by systematically searching electronic databases and grey literature to identify relevant metabolomics studies on schistosomiasis. Arksey and O&#x2019;Malley methodology for conducting systematic scoping reviews was applied. A narrative summary of results was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for scoping review guidelines.</p>
</sec>
<sec>
<title>Results</title>
<p>Twelve articles included in the review identified 127 metabolites, whose concentrations were considerably altered during <italic>S. mansoni</italic> and <italic>S. haematobium</italic> infections. The metabolites were assigned to metabolic pathways involved in energy (34.6%), gut microbial (11.0%), amino acid (25.2%), nucleic acids (6.3%), immune proteins (8.7%) hormones (2.4%) and structural proteins/lipids (11.8%). Energy related metabolic pathways were the most affected during schistosome infections with metabolites such as succinate, citrate, aconitate and fumarate of the tricarbocylic acid cycle being significantly altered in organ, serum and plasma samples. Amino acid metabolism was also impacted during schistosome infections as phenylacetylglycine, alanine, taurine, 2-oxoisocaproate and 2-oxoisovalerate emerged as potent biomarkers. Elevated structural proteins such as actin, collagen and keratin concentrations were identified as biomarkers of liver fibrosis, a common pathological feature in chronic schistosomiasis infections. Hippurate was a major metabolite biomarker in the gut microbial related pathway.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>The analysis of the literature revealed that energy related metabolic pathways are considerably altered during <italic>S. mansoni</italic> and <italic>S. haematobium</italic> infections. Therefore, their metabolites may provide biomarkers for diagnosis and prognosis in addition to providing therapeutics for parasitic infections. This scoping review has identified a need to replicate more schistosomiasis metabolomic studies in humans to complement animal-model based studies.</p>
</sec>
</abstract>
<kwd-group>
<kwd>metabolites</kwd>
<kwd>biomarkers</kwd>
<kwd>
<italic>S. haematobium</italic>
</kwd>
<kwd>
<italic>S. mansoni</italic>
</kwd>
<kwd>schistosomiasis</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="74"/>
<page-count count="11"/>
<word-count count="5360"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Schistosomiasis is one of the common neglected tropical diseases (NTDs) caused by sexually dimorphic helminth worms of the genus <italic>Schistosoma</italic> (<xref ref-type="bibr" rid="B1">1</xref>). Global estimates show a prevalence of at least 236.6 million cases in 78 countries (<xref ref-type="bibr" rid="B2">2</xref>). Moreover, 200 000 deaths are recorded annually, especially in Africa which accounts for 90% of global morbidity and mortality (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Of the six known human schistosome species, <italic>Schistosoma haematobium</italic> (<italic>S. haematobium</italic>) and <italic>Schistosoma mansoni</italic> (<italic>S. mansoni</italic>) are the main etiological agents of human urogenital and intestinal schistosomiasis respectively and are highly prevalent in the sub-Saharan region (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Early diagnosis of schistosomiasis is key for effective treatment and management of adverse symptoms which directly determine the clinical outcome of the disease, whilst development of vaccine against helminth infections is critical in the eradication of the disease (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Low sensitivity diagnostic tools in detection of early or light schistosome infections across all age groups particularly in pre-school aged children (PSAC) &#x2264;5 years have implicated worldwide concerted efforts in schistosome surveillance and control programmes (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). Furthermore, there is no approved effective vaccine for schistosomiasis (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>In addition to providing insight into complex immunopathology during schistosomiasis (<xref ref-type="bibr" rid="B11">11</xref>), metabolite biomarkers of infection are critical to the rational development of therapeutic interventions (<xref ref-type="bibr" rid="B12">12</xref>), non-invasive diagnostic and prognostic tools (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>) thus it is of paramount significance to characterise schistosome induced metabolic alterations. In recent years, metabolomics has emerged as a powerful omics approach in characterisation of host metabolic responses to infections at a molecular level leading to a wide range of applications in discovery of drug targets and novel biomarkers in infectious diseases (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Preventive chemotherapy alone is insufficient in the global control and elimination of schistosomiasis. Thus integrated approaches should include; inclusion of all age groups in control strategies, effective diagnosis, knowledge on efficacy of treatment, provision of good sanitary conditions (<xref ref-type="bibr" rid="B17">17</xref>). Moreover, a clear understanding of the infection pathology dynamics or health impacts in all age groups have to be established (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). Diagnosis and knowledge in pathological mechanisms are the main factors that determine the success of schistosomiasis management strategies. This has led to concerted efforts in the search of new biomarkers by analysing metabolic pathway dysregulation using a metabolomics based approach (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). The available standard methods specifically urine filtration technique for <italic>S. haematobium</italic> and Kato Katz technique for <italic>S. mansoni</italic> lacks sensitivity and absolute specificity. These diagnosis shortfalls are even more in areas where the disease burden is low and in patients with light schistosome infection (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>The maximum impact of global control and elimination programs for schistosomiasis may be realised through addressing above challenges. Metabolomics is a more holistic approach as far as schistosomiasis diagnosis, prognosis, provision of therapeutic drug or vaccine targets. A metabolomics approach would also allow for the elucidation of infection mechanisms <italic>via</italic> analysis of metabolic pathway alterations and characterising metabolite signatures for biomarkers (<xref ref-type="bibr" rid="B24">24</xref>). Against this background, we highlight the metabolic alterations for biomarker discovery during urogenital and intestinal schistosomiasis.</p>
<p>In this scoping review we sought to summarize metabolic biomarkers associated with <italic>S. haematobium</italic> and <italic>S. mansoni</italic> infections to facilitate understanding of disease mechanisms and the discovery of unique diagnostics and therapeutic measures. The following review questions were answered:</p>
<list list-type="order">
<list-item>
<p>Which metabolites can be utilized as biomarkers of <italic>S. haematobium</italic> and <italic>S. mansoni</italic> infections?</p>
</list-item>
<list-item>
<p>Which metabolic pathway alterations occur during <italic>S. haematobium</italic> and <italic>S. mansoni</italic> infections?</p>
</list-item>
</list>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<p>Our methodology for the study was informed by the Arksey and O&#x2019;Malley (<xref ref-type="bibr" rid="B25">25</xref>) guidance for conducting systematic scoping reviews. A comprehensive systematic literature search relevant to the topic and review objectives was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines (<xref ref-type="supplementary-material" rid="ST1">
<bold>Table S1</bold>
</xref>) (<xref ref-type="bibr" rid="B26">26</xref>). The&#xa0;protocol for the scoping review was registered in Open Science Framework (osf.io/py3x9).</p>
<sec id="s2_1">
<label>2.1</label>
<title>Data sources and search Strategy</title>
<p>Four electronic bibliographic databases (Pubmed, Cochrane Library, Medline and Embase) were searched using the following search terms, modified appropriately to each or for each database: (1) (metabolome OR metabolomics OR metabolomic OR metabonomics OR metabonomic OR metabolite OR metabolic OR metabolism OR lipidome OR lipidomics OR lipidomic OR proteome OR proteomics OR proteomic) and (2) (schistosomiasis OR bilharziasis OR bilharzia OR katayama fever OR snail fever OR urogenital schistosomiasis OR urinary schistosomiasis OR genital schistosomiasis OR <italic>Schistosoma</italic> OR <italic>haematobium</italic> OR <italic>Schistosoma haematobium</italic> OR <italic>S. haematobium</italic> OR <italic>Schistosoma mansoni</italic> OR <italic>S. mansoni</italic> OR <italic>mansoni</italic> OR intestinal schistosomiasis). Databases were searched from inception without any language restrictions. In addition to the primary databases we complemented the search strategy by searching of grey literature and unpublished preprints in MedRxiv and BioRxiv. The search strategies and results for all databases are illustrated in <xref ref-type="supplementary-material" rid="ST4">
<bold>File S1</bold>
</xref>.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Eligibility criteria</title>
<p>Animal and human case cohort, case-control and prospective cohort studies of all age groups with <italic>S. haematobium</italic> or <italic>S. mansoni</italic> infections were included in the review. The studies were eligible if metabolomics methods, mainly but not limited to; nuclear magnetic resonance (NMR), gas chromatography (GS), liquid chromatography (LC), mass spectrometry (MS) or combinations of these approaches were utilised to identify biomarkers or changes of metabolites between schistosomiasis patients and controls or uninfected individuals. Articles with outcomes which clearly highlight significant alterations to specific metabolic pathways due to infection and where candidate biomarkers were defined by the researcher as any substance or its product/s that may be quantified in a predefined biological sample were also considered. Studies relating to other forms of schistosome infections (such as <italic>S. japonicum</italic>, <italic>S. intercalatum</italic> and <italic>S. mekongi</italic>), articles irrelevant to metabolomics of schistosomiasis, abstracts without full texts, text books, letters and review articles were excluded.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Study selection and data chatting</title>
<p>Zotero (version 5.0.96.3) program was used for bibliography management. Two independent authors screened the titles and abstracts retrieved by the search in the databases and excluded articles that were clearly opposed to our inclusion criteria whilst full articles were retrieved for the studies that were best aligned to the review questions. A comprehensive full text screening was conducted for eligibility of the studies and any disagreements in the final selection process were reconciled through discussion between authors and where agreement could not be reached, third reviewer was involved in the process to avoid the risk of bias in acceptance or rejection of the studies.</p>
<p>Authors subsequently extracted the following information from the eligible studies included (see <xref ref-type="supplementary-material" rid="ST2">
<bold>Table S2</bold>
</xref>) for the current review:</p>
<list list-type="order">
<list-item>
<p>study profile (authors, DOI, year of publication, country),</p>
</list-item>
<list-item>
<p>study design and aims</p>
</list-item>
<list-item>
<p>targeted population</p>
</list-item>
<list-item>
<p>type of metabolomics analytical platform</p>
</list-item>
<list-item>
<p>sample size, including number of cases and controls</p>
</list-item>
<list-item>
<p>specimen type (serum, plasma, urine, organ and faecal)</p>
</list-item>
<list-item>
<p>metabolites or pathway identified (including concentration increase or decrease)</p>
</list-item>
<list-item>
<p>statistical approach for data analysis</p>
</list-item>
</list>
<p>Reasons for study exclusion was also extracted for all excluded articles (see <xref ref-type="supplementary-material" rid="ST3">
<bold>Table S3</bold>
</xref>).</p>
</sec>
<sec id="s2_4">
<label>2.3</label>
<title>Methodological quality appraisal and data synthesis</title>
<p>For the current review, there is no critical appraisal of methodological quality or risk of bias of the included study articles in relation to guidance on scoping review conduct (<xref ref-type="bibr" rid="B27">27</xref>). However, quantitative descriptive analysis was carried out simultaneously with a qualitative thematic analysis whilst a comprehensive narrative summary was employed to interpret the tabulated findings within the context of the objective and questions of this review (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B28">28</xref>).</p>
</sec>
</sec>
<sec id="s3">
<label>3</label>
<title>Results and discussion</title>
<sec id="s3_1">
<label>3.1</label>
<title>Inclusion of studies</title>
<p>The scoping review aggregated human and animal metabolomics studies with an emphasis on metabolite and metabolic pathway perturbations that have potential biomarker value in urogenital and intestinal schistosomiasis caused by <italic>S. haematobium</italic> and <italic>S. mansoni</italic> respectively. A total of 3118 articles were found from seven electronic databases. Following the removal of duplicates, 1208 articles remained for screening. Two researchers independently screened the studies using the title or abstract and 93 articles were sort for full text retrieval. Post assessment, a total of 12 articles were included in this review conforming to outlined eligibility, whilst 81 articles were excluded predominantly due to a lack of high throughput metabolomics techniques in their methodology (n=66). <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> illustrates the PRISMA flow diagram for the study&#x2019;s literature search and identification method.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>PRISMA flow diagram of search and article selection.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fitd-04-1108317-g001.tif"/>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Study characteristics</title>
<p>The general characteristics of the articles included in this review are shown in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. Based on literature survey, the majority of the metabolomics studies focused on <italic>S. mansoni</italic> species (n=10) whilst 2 studies concentrated on <italic>S. haematobium</italic> species. In terms of models, 7 studies used animals (mice), 4 studies used humans&#x2019; specimens and 1 study included both human and animal models. Biological samples included plasma in 3 studies, serum in 2 studies, urine in 11 studies, tissue or organ in 3 studies and faecal in 1 study. One study (<xref ref-type="bibr" rid="B33">33</xref>) utilized urine, plasma and faecal, three studies (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B35">35</xref>) utilized organs (either liver, jejunum, ileum, colon, spleen and kidney) and one study (<xref ref-type="bibr" rid="B21">21</xref>) utilized urine and plasma. The analytical platforms applied to detect metabolic perturbations, included nuclear magnetic resonance (NMR) based in 4 studies, ultra-high performance liquid chromatography (UHPLC) in 3 studies, liquid chromatography mass spectrometry (LC-MS) in 1 study, capillary electrophoresis time-of-flight mass spectrometry (CE-TOF-MS) in 1 study, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in 2 studies, gas chromatography mass spectrometry (GC&#x2013;MS) in 1 study, two-dimensional difference gel electrophoresis (2D DIGE) in 2 studies and capillary electrophoresis (CE) in 1 study. These platforms were either utilised in targeted metabolomics approach which is the comprehensive analysis of all metabolites or untargeted metabolomics approach which is a subset analysis of specifically defined metabolites. The approach for these analytical platforms in biomarker identification included 9 studies in untargeted and 3 studies in targeted metabolomics. The most frequently reported metabolic pathway was energy related in 9 studies followed by amino acids in 7 studies, gut microbial related in 6 studies, structural proteins or lipids in 5 studies, immune proteins in 2 studies and 1 study for hormone and nucleic acid metabolism respectively.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Summary of the studies used to evaluate the metabolomic responses during schistosomiasis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">SN</th>
<th valign="top" align="center">First author</th>
<th valign="top" align="center">Geographic location</th>
<th valign="top" align="center">Species</th>
<th valign="top" align="center">Model</th>
<th valign="top" align="center">Sample size (Cases/Controls)</th>
<th valign="top" align="center">Sample</th>
<th valign="top" align="center">Approach/platform</th>
<th valign="top" align="center">Key metabolic pathway altered</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>1</bold>
</td>
<td valign="top" align="left">Wang et&#xa0;al. (2004) (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td valign="top" align="left">Switzerland</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Mice</td>
<td valign="top" align="left">N=20:<break/>Infected (n=10)<break/>Healthy controls (n=10)]</td>
<td valign="top" align="left">Urine</td>
<td valign="top" align="left">Untargeted:<break/>1H NMR</td>
<td valign="top" align="left">Energy related (TCA and glycolysis), amino acid synthesis and gut microbial related</td>
</tr>
<tr>
<td valign="top" align="left">2</td>
<td valign="top" align="left">Garc&#xed;a-P&#xe9;rez et&#xa0;al. (2010) (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td valign="top" align="left">Spain</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Mice</td>
<td valign="top" align="left">N=20:<break/>Infected (n=10)<break/>Healthy controls (n=10)</td>
<td valign="top" align="left">Urine</td>
<td valign="top" align="left">Targeted: CE</td>
<td valign="top" align="left">Energy related, gut microbial related, urea and amino acid</td>
</tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="left">Li et&#xa0;al. (2009) (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td valign="top" align="left">Switzerland</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Mice</td>
<td valign="top" align="left">N=20:<break/>Infected (n=10),<break/>Healthy controls (n=10)</td>
<td valign="top" align="left">Jejunum, Ileum, Colon, Liver, Spleen, Kidney</td>
<td valign="top" align="left">Untargeted: 1H MAS-NMR</td>
<td valign="top" align="left">Energy related metabolism (lipids, glucose and glycogen)<break/>and amino acids</td>
</tr>
<tr>
<td valign="top" align="left">4</td>
<td valign="top" align="left">Manivannan et&#xa0;al.(2012) (<xref ref-type="bibr" rid="B32">32</xref>)</td>
<td valign="top" align="left">Kenya</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Mice</td>
<td valign="top" align="left">N=15:<break/>Health controls (n=5)<break/>Infected group A (n=5)<break/>Infected group B (n=5)</td>
<td valign="top" align="left">Liver, Serum</td>
<td valign="top" align="left">Untargeted: 2D-DIGE; MALDI-TOF MS</td>
<td valign="top" align="left">Energy related, structural proteins/lipids and immune proteins</td>
</tr>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="left">Li et&#xa0;al.(2011) (<xref ref-type="bibr" rid="B33">33</xref>)</td>
<td valign="top" align="left">Switzerland</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Mice</td>
<td valign="top" align="left">N=10:<break/>Infected (n=5)<break/>Healthy controls (n=5)</td>
<td valign="top" align="left">Urine, Plasma, Faecal</td>
<td valign="top" align="left">Untargeted: 1H NMR</td>
<td valign="top" align="left">Energy related, gut microbial related and liver metabolism</td>
</tr>
<tr>
<td valign="top" align="left">6</td>
<td valign="top" align="left">Balog et&#xa0;al. (2011) (<xref ref-type="bibr" rid="B34">34</xref>)</td>
<td valign="top" align="left">Uganda</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Human</td>
<td valign="top" align="left">N=335:<break/>Infected and healthy control varied at each 5 five follow-up time points for school aged children (n=159) and adults (n=176)</td>
<td valign="top" align="left">Urine</td>
<td valign="top" align="left">Untargeted: 1H NMR</td>
<td valign="top" align="left">Energy related and gut microbial related</td>
</tr>
<tr>
<td valign="top" align="left">7</td>
<td valign="top" align="left">Manivannan et&#xa0;al. (2011) (<xref ref-type="bibr" rid="B35">35</xref>)</td>
<td valign="top" align="left">Kenya</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Human, Mice</td>
<td valign="top" align="left">Mice N=15:<break/>healthy controls (n=5), infected (n=10) grouped 5 each according to severity;<break/>Human N=50:<break/>Healthy controls (n=13), infected (n=37)</td>
<td valign="top" align="left">Mice: Liver, Serum Human: Serum</td>
<td valign="top" align="left">Targeted: 2D-DIGE; MALDI-TOF MS</td>
<td valign="top" align="left">Energy related and gut microbial</td>
</tr>
<tr>
<td valign="top" align="left">8</td>
<td valign="top" align="left">Onile et&#xa0;al. (2017) (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td valign="top" align="left">Nigeria</td>
<td valign="top" align="left">
<italic>S. haematobium</italic>
</td>
<td valign="top" align="left">Human</td>
<td valign="top" align="left">N=49:<break/>Infected only (n=12)<break/>Bladder pathology only (n=12), Combined pathology and infected (n=15)<break/>Health controls (n=10)]</td>
<td valign="top" align="left">Urine</td>
<td valign="top" align="left">Untargeted: UHPLC</td>
<td valign="top" align="left">Structural proteins/lipids (membrane associated, nuclear based, cytoplasmic, cytoskeletal, mitochondrial and ribosomal)</td>
</tr>
<tr>
<td valign="top" align="left">9</td>
<td valign="top" align="left">Adebayo et&#xa0;al. (2018) (<xref ref-type="bibr" rid="B21">21</xref>)</td>
<td valign="top" align="left">Nigeria</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Human</td>
<td valign="top" align="left">N=111:<break/>Infected (n=65),<break/>Healthy controls (n=46)</td>
<td valign="top" align="left">Urine, Plasma</td>
<td valign="top" align="left">Untargeted: UHPLC</td>
<td valign="top" align="left">Structural proteins/lipids (catechols, choline and fatty acids sphingolipid, glycerophospholipid) and hormones (sex steroids)</td>
</tr>
<tr>
<td valign="top" align="left">10</td>
<td valign="top" align="left">Osakunor et&#xa0;al. (2020) (<xref ref-type="bibr" rid="B37">37</xref>)</td>
<td valign="top" align="left">Zimbabwe</td>
<td valign="top" align="left">
<italic>S. haematobium</italic>
</td>
<td valign="top" align="left">Human</td>
<td valign="top" align="left">N=83:<break/>Infected (n=11)<break/>Healthy controls (n=72)</td>
<td valign="top" align="left">Serum</td>
<td valign="top" align="left">Untargeted: CE&#x2013;TOF&#x2013;MS</td>
<td valign="top" align="left">Energy related (glycolysis, pentose phosphate pathway, fatty acid/lipid synthesis, gluconeogenesis and glycogenolysis) and nucleic acid metabolism (purines)</td>
</tr>
<tr>
<td valign="top" align="left">11</td>
<td valign="top" align="left">Bexkens et&#xa0;al. (2020) (<xref ref-type="bibr" rid="B38">38</xref>)</td>
<td valign="top" align="left">Netherlands</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Mice</td>
<td valign="top" align="left">N=10:<break/>Infected (n=5)<break/>Healthy controls (n=5)</td>
<td valign="top" align="left">Plasma</td>
<td valign="top" align="left">Targeted: UHPLC; LC&#x2013;MS/MS</td>
<td valign="top" align="left">Structural proteins/lipids: (extracellular vesicles lipid and protein content)</td>
</tr>
<tr>
<td valign="top" align="left">12</td>
<td valign="top" align="left">Loyo et&#xa0;al. (2021) (<xref ref-type="bibr" rid="B39">39</xref>)</td>
<td valign="top" align="left">New Zealand</td>
<td valign="top" align="left">
<italic>S. mansoni</italic>
</td>
<td valign="top" align="left">Mice</td>
<td valign="top" align="left">N=24:<break/>Infected (light) (n=8),<break/>Infected (heavy) (n=8),<break/>Healthy controls (n=8)</td>
<td valign="top" align="left">Urine</td>
<td valign="top" align="left">Untargeted: GC-MS</td>
<td valign="top" align="left">Energy related (glycolysis, tricarboxylic acid cycle), amino acid and gut microbial</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>CE, capillary electrophoresis; UPHPLC, ultra-high performance liquid chromatography; 2D DIGE, two-dimensional difference gel electrophoresis; CE&#x2013;TOF&#x2013;MS, capillary electrophoresis time-of-flight mass spectrometry; NMR, nuclear magnetic resonance; LC-MS, liquid chromatography mass spectrometry; GC-MS, gas chromatography mass spectrometry; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Metabolomic pathways</title>
<sec id="s3_3_1">
<label>3.3.1</label>
<title>Global profile of metabolites</title>
<p>For a global metabolomics profile, the altered metabolic pathways were divided into seven different categories namely energy, gut microbial, amino acids, nucleic acids, immune proteins, structural proteins/lipids and hormone related metabolites. From the studies included in this scoping review, a total of 127 altered metabolites were extracted in response to <italic>S. haematobium</italic> and <italic>S. mansoni</italic> infections in which 90 were unique non repeated metabolites. Furthermore, 44 repeats (frequency in which the metabolite is determined to be a biomarker in a study) of 17 different metabolites were identified in these seven metabolic pathway categories. With respect to energy metabolism, a total of 44 energy related metabolites with 12 repeats of 7 different metabolites were identified while 14 gut microbial related metabolites containing 11 repeats of 3 different metabolites and 8 different nucleic acid related metabolites were identified. With respect to amino acid metabolism, 32 metabolites were found to be altered with 17 repeats of 7 different metabolites. Finally, a total of 11 metabolites, 15 metabolites and 3 metabolites were identified for immune proteins, structural lipids or protein and hormone metabolism respectively. Comparison of all extracted metabolites revealed that the energy metabolism was significantly affected as their metabolites deviate from normal concentrations in schistosomiasis infected individuals as compared to healthy controls, followed by amino acid, structural lipids or protein, gut microbial, immune proteins, nucleic acid and hormones metabolism. Adult schistosome worms utilise glucose ranging from one-sixth to one-fifth of its dry weight leading to energy related metabolites, enzyme and intermediate deviations from their homeostatic level which may explain the reason for a high number in energy related metabolism related biomarkers in schistosomiasis (<xref ref-type="bibr" rid="B40">40</xref>). <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> provides an overview of key altered metabolites from the studies pathway enrichment analysis on the extracted metabolites and manual assignment of the metabolites to pathway.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Summary of changes in major affected metabolic pathways during urogenital and intestinal schistosomiasis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Metabolic pathway</th>
<th valign="top" align="center">Increased</th>
<th valign="top" align="center">Decreased</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Energy</td>
<td valign="top" align="left">lactate (<xref ref-type="bibr" rid="B29">29</xref>), creatine (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B34">34</xref>), pyruvate (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B32">32</xref>), citric acid cycle glycolic (<xref ref-type="bibr" rid="B30">30</xref>), carboxylase, dimethylglycine dehydrogenase, sarcosine dehydrogenase, major urinary protein (<xref ref-type="bibr" rid="B32">32</xref>), lipid fractions (<xref ref-type="bibr" rid="B33">33</xref>), acetate (<xref ref-type="bibr" rid="B34">34</xref>) putative adenosine diphosphate/adenosine triphosphate carrier proteins (<xref ref-type="bibr" rid="B36">36</xref>)glucose-6-phosphate, ethanolamine phosphate, 3-phosphoglyceric acid (<xref ref-type="bibr" rid="B37">37</xref>) malonate, alpha ketoglutarate, succinate, fumarate, methylmalonate and ribitol (<xref ref-type="bibr" rid="B39">39</xref>);</td>
<td valign="top" align="left">citrate (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B34">34</xref>), succinate, short-chain fatty acids, D-3 hydroxybutyrate, 2-oxoglutarate (<xref ref-type="bibr" rid="B29">29</xref>), glucose, glycogen (<xref ref-type="bibr" rid="B31">31</xref>), lipid signals, D-3-hydroxybutyrate, acetate, creatine, glucose, citrate (<xref ref-type="bibr" rid="B33">33</xref>), 2-oxoglutarate, fumarate, succinate (<xref ref-type="bibr" rid="B34">34</xref>), aconitate (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>), major urinary protein (<xref ref-type="bibr" rid="B35">35</xref>) and lactic acid (<xref ref-type="bibr" rid="B37">37</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Gut microbial</td>
<td valign="top" align="left">p-cresol glucuronide (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>), trimethylamine (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>), trimethylamine N-oxide (<xref ref-type="bibr" rid="B34">34</xref>), 5-aminovalerate, propionate (<xref ref-type="bibr" rid="B33">33</xref>) and hippurate in light infections (<xref ref-type="bibr" rid="B39">39</xref>)</td>
<td valign="top" align="left">acetate, butyrate, propionate (<xref ref-type="bibr" rid="B29">29</xref>), dimethylamine (<xref ref-type="bibr" rid="B34">34</xref>) and hippurate (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Nucleic acid</td>
<td valign="top" align="left">uric acid (<xref ref-type="bibr" rid="B30">30</xref>), guanidino acetate, methylguanidine (<xref ref-type="bibr" rid="B34">34</xref>) cyclic adenosine monophosphate response element binding protein (<xref ref-type="bibr" rid="B21">21</xref>) adenosine diphosphate, adenosine monophosphate and inosine (<xref ref-type="bibr" rid="B37">37</xref>)</td>
<td valign="top" align="left">Nil</td>
</tr>
<tr>
<td valign="top" align="left">Amino acid</td>
<td valign="top" align="left">phenylacetylglycine (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>), alanine (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B39">39</xref>), tryptophan (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>) benzoic acid, asparagine (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B37">37</xref>), leucine, isoleucine, lysine, glutamine and a sparagine (<xref ref-type="bibr" rid="B31">31</xref>), indolylacryloylglycine (<xref ref-type="bibr" rid="B21">21</xref>) and glycine (<xref ref-type="bibr" rid="B39">39</xref>)</td>
<td valign="top" align="left">taurine, 2-oxoisovalerate (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>), urea (<xref ref-type="bibr" rid="B30">30</xref>), 2-oxoisocaproate (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>), oxoadipate [37], glutamic acid, histidine, serine (<xref ref-type="bibr" rid="B37">37</xref>) and lysine (<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Immune proteins</td>
<td valign="top" align="left">Major histocompatibility complex class I precursors, lymphocyte cytosolic protein 1, prohibitin 2 (<xref ref-type="bibr" rid="B32">32</xref>) <italic>S. mansoni</italic> phosphoenolpyruvate carboxykinase (SmPEPCK) (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B35">35</xref>) IL-2 (<xref ref-type="bibr" rid="B35">35</xref>) venom allergen-like (VAL) 3 proteins (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td valign="top" align="left">peroxiredoxin 6 (<xref ref-type="bibr" rid="B35">35</xref>) Complement C4 isoform and alpha-1-inhibitor-3 like (<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Structural proteins and lipids</td>
<td valign="top" align="left">glycerophosphoryl choline, phosphoryl choline (<xref ref-type="bibr" rid="B33">33</xref>) actins, collagen (<xref ref-type="bibr" rid="B32">32</xref>), cytokeratin 18, cytokeratin 8, hydroxyproline, connective tissue growth factor (<xref ref-type="bibr" rid="B35">35</xref>), heat shock protein (HSP) 70, HSP60, tubulin alpha chain elongation factor 1-alpha (<xref ref-type="bibr" rid="B36">36</xref>), phosphatidylcholine, phosphatidylethanolamine (<xref ref-type="bibr" rid="B21">21</xref>) and extracellular vesicle proteins (<xref ref-type="bibr" rid="B38">38</xref>)</td>
<td valign="top" align="left">phosphatidylcholine (<xref ref-type="bibr" rid="B33">33</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Hormones</td>
<td valign="top" align="left">adrenochrome O-quinone (<xref ref-type="bibr" rid="B21">21</xref>)</td>
<td valign="top" align="left">modified estradiol and estosterone (sex steroids) (<xref ref-type="bibr" rid="B21">21</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_3_2">
<label>3.3.2</label>
<title>Energy metabolic pathways</title>
<p>Energy metabolic pathways are critical to all living organisms through production of ATP to effectuate the bioenergetic need of cellular functions and processes contributing to net biomass formation and homeostasis (<xref ref-type="bibr" rid="B41">41</xref>). In the current review, schistosome infection was reported to upregulate glycolysis which was indicated by an increase in intermediates (glucose-6-phosphate and 3-phosphoglyceric acid) and their end product pyruvate whilst the main substrate glucose and its stores declined (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Furthermore, glucose-6-phoshate and 3-phosphoglyceric acid were found to be major metabolite biomarkers in discriminating human <italic>S. haematobium</italic> infection in paediatrics below the age of five (<xref ref-type="bibr" rid="B37">37</xref>). A study conducted by Tielens and colleagues highlighted that during the helminth complex life cycle in mammalian hosts, paired adult schistosomes utilise glucose and glycogen for their maturation and to compensate for their substantial needs for the energy required to produce the large numbers of eggs laid continuously by the female worm (<xref ref-type="bibr" rid="B42">42</xref>). Consequently, enhanced activation of glycolysis was reported to directly stimulate the tricarboxylic acid cycle as exhibited by high levels of pathway intermediates such as alpha ketoglutarate (<xref ref-type="bibr" rid="B39">39</xref>). However, tricarboxylic acid intermediates, succinate and fumerate were considered poor diagnostic markers as they may be inconclusively lower or higher in concentration during schistosome infection (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Aconitate levels were reported to be significantly decreased during <italic>S. mansoni</italic> infection, thus may be a potent oxidative biomarker (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). The findings of Yarian and colleagues suggest that perturbations of aconitase is associated with aging and disturbances in the tricarboxylic acid cycle activities leading to reduction in overall capability of mitochondrial bioenergetics (<xref ref-type="bibr" rid="B43">43</xref>).</p>
</sec>
<sec id="s3_3_3">
<label>3.3.3</label>
<title>Gut microbial metabolism</title>
<p>Helminth infections contribute to the structure and composition of the gut microbiome which play a major role in the development of the immune system (<xref ref-type="bibr" rid="B44">44</xref>). The studies in this review showed that hippurate is a major candidate microbiome biomarker during intestinal and urogenital schistosomiasis and the reduction in the metabolite concentration in biofluids is associated with infection (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). Furthermore, one study reported that hippurate concentration is elevated during light schistosome infection while the concentration is decreased in chronic schistosome infection hence the metabolite may be used as a marker to determine the intensity of infection (<xref ref-type="bibr" rid="B39">39</xref>). Elevated levels of triethylamine and <italic>p</italic>-cresol glucuronide were significantly associated with schistosome infection despite other microbiome metabolites such as trimethylamine N-oxide and aminovalerate detection being elevated in urine and plasma (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). The presence of microbial based metabolites such as hippurate, <italic>p</italic>-cresol glucuronide and trimethylamine derivatives in biofluids suggest a cross-talk between helminth worms in mammalian host and its gut microbiota therefore such unique biomarkers may be utilised in the development of new diagnostic tools for schistosomiasis (<xref ref-type="bibr" rid="B33">33</xref>). However, propionate had indeterminate pertubations as the metabolite may either be decreased or increased during schistosome infections, hindering its predictor value as a gut microbiota biomarker (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>).</p>
</sec>
<sec id="s3_3_4">
<label>3.3.4</label>
<title>Nucleic acid metabolism</title>
<p>Urogenital schistosomiasis alters nucleic acid metabolism by increasing the synthesis of purines mainly inosine, AMP and ADP (<xref ref-type="bibr" rid="B37">37</xref>). Two studies supported the findings as purine derived metabolites namely guanidino acetate, methylguanidine cyclic adenosine monophosphate response element binding protein were elevated during schistosomiasis (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B34">34</xref>). A possible explanation for the upregulation of purine metabolism is an increase in demand for energy in the form of ATP by schistosome worms, which consequently increase ADP and AMP as products of hydrolysis (<xref ref-type="bibr" rid="B21">21</xref>). Additionally, the concentrations of the high energy phosphates, AMP and ADP in the blood are key regulators of energy homeostasis as they determine the initiation of alternative metabolic pathways such as fatty acid degradation and glycogenolysis to restore energy balance (<xref ref-type="bibr" rid="B37">37</xref>).</p>
</sec>
<sec id="s3_3_5">
<label>3.3.5</label>
<title>Amino acid metabolism</title>
<p>Amino acid functions are not only limited as structural building blocks of proteins or nutritional elements but are also involved in a myriad of biological processes which include acting as regulatory signals for gene expression, cell signalling pathways and being precursor molecules for hormone synthesis (<xref ref-type="bibr" rid="B21">21</xref>). Schistosome infection resulted in elevated levels of phenylacetylglycine and alanine (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Phenylacetylglycine is an alpha amino acid which bears an acyl group at its terminal nitrogen atom that signals a lysosomal disorder called phospholipidosis where there is an over accumulation of phospholipids in either the liver, kidney or lungs (<xref ref-type="bibr" rid="B45">45</xref>). The disorder can be linked to hepatosplenomegaly due to entrapment of schistosome eggs in the liver and spleen (<xref ref-type="bibr" rid="B46">46</xref>). An increase in glucogenic amino acids (alanine, glutamine and asparagine) was observed in both <italic>S. mansoni</italic> and <italic>S. haematobium</italic> infections (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Elevated levels in glucogenic amino acids may be attributed to upregulation of gluconeogenesis due to depletion of energy substrates and elevated liver aminotransferases (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Free proline, which is a precursor of hydroxyproline, glycine, alanine and their derivatives, were elevated in <italic>S. mansoni</italic> infections in mouse models which might imply stimulated collagen synthesis activity (<xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>A disturbance of amino acid metabolic pathways was also associated with an <italic>S. mansoni</italic> infection, as indicated by the depletion of taurine, 2-oxoisocaproate and 2-oxoisovalerate. Taurine is an amino sulfonic acid that has been reported to alleviate liver fibrosis by suppressing the activation of downstream inflammatory mediators and subsequent pyroptosis (<xref ref-type="bibr" rid="B50">50</xref>). A decrease in 2-oxoisocaproate and 2-oxoisovalerate that originates from valine and leucine respectively was reported to be associated with increase in amino acid metabolism to synthesise precursor molecules (<xref ref-type="bibr" rid="B29">29</xref>). Notably, one study indicated a decrease in urea which may be due to expression of arginase induced by schistosome worms during their development in the human host, which is responsible for the hydrolysis of urea (<xref ref-type="bibr" rid="B51">51</xref>).</p>
</sec>
<sec id="s3_3_6">
<label>3.3.6</label>
<title>Immune proteins</title>
<p>
<italic>S. mansoni</italic> phosphoenolpyruvate carboxykinase (SmPEPCK) is an egg antigen for schistosome infection and studies suggested its potential as a disease specific protein marker due to its immunological properties (<xref ref-type="bibr" rid="B52">52</xref>). SmPEPCK was detected and elevated in the liver during intestinal schistosomiasis (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B35">35</xref>), therefore this protein-based antigen may be utilised as an immunological marker of infection adding to serum cytokines, chemokines and receptors (<xref ref-type="bibr" rid="B53">53</xref>). Lymphocyte cytosolic protein 1 (LCP1) and prohibitin 2 were significantly increased in schistosome chronic infections (<xref ref-type="bibr" rid="B32">32</xref>). LCP1 has been reported to be utilised as a marker in cancers such as leukaemia whilst the latter controls the growth, development and apoptosis of cells thus it can be concluded that they are not useful markers for schistosomiasis (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). Major histocompatibility complex (MHC) precursors and interleukin-2 (IL-2) were found to be increased during the infection. The MHC plays an important role in adaptive immunity through presentation of both endogenous and exogenous antigens during helminths infections (<xref ref-type="bibr" rid="B56">56</xref>). A surge in cytokine IL-2 have been reported in both <italic>S. haematobium</italic> and <italic>S. mansoni</italic> infections to promote the growth and development of peripheral immune cells in the initiation of the immune response (<xref ref-type="bibr" rid="B57">57</xref>). One study reported elevated levels of venom allergen-like (VAL) 3 proteins during schistosomiasis which is a common feature of helminths species cocktail of proteins to aid invasion, initiate feeding, facilitate adaptation and mediate modulation of the host immune responses (<xref ref-type="bibr" rid="B58">58</xref>).</p>
</sec>
<sec id="s3_3_7">
<label>3.3.7</label>
<title>Structural proteins and lipid metabolism</title>
<p>Lipids play a major role in the formation or maintenance of the integrity of the cellular membrane bilayer and act as receptors for a variety of cell signalling processes (<xref ref-type="bibr" rid="B59">59</xref>). Membrane associated lipids namely glycerophosphoryl choline, phosphoryl choline and phosphatidylethanolamine are elevated in the blood during schistosomiasis infections (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B38">38</xref>). However, two studies were contradicting with respect to phosphatidylcholine; one study (<xref ref-type="bibr" rid="B21">21</xref>) indicated that the levels were elevated whilst the other showed that the levels were decreased in during schistosomiasis (<xref ref-type="bibr" rid="B33">33</xref>). Disturbance in phosphocholine concentration in tissues is associated with cell proliferation which additionally explains elevated heat shock proteins (HSP) as oncogene signalling molecules (<xref ref-type="bibr" rid="B60">60</xref>). Due to oxidative stress in a tumour microenvironment, phosphatidylethanolamine is usually expressed on endothelial cells and has been reported that alterations in both phosphatidylethanolamine and phosphatidylcholine is one of the mechanisms for carcinogenesis in chronic infections (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Secondary structure proteins; actins, collagen, cytokeratins, hydroxyproline and connective tissue growth factor were elevated during schistosomiasis infections with a possibility in playing a role in liver fibrosis in chronic schistosome infections (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B36">36</xref>).</p>
</sec>
<sec id="s3_3_8">
<label>3.3.8</label>
<title>Hormones</title>
<p>Low levels of human estrogen-related hormones were associated with urogenital schistosomiasis infection (<xref ref-type="bibr" rid="B21">21</xref>). There is existing evidence for the role of estrogen metabolism in host-parasite relationship where <italic>S. haematobium</italic> adult worm utilise or inhibit production of host steroids resulting in decreased sex steroid hormones (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). On the other hand, adrenochrome-O-quinone, a toxic quinone metabolite of epinephrine, was elevated in plasma during schistosomiasis infection. Adrenocromes with quinone groups are capable of forming reactive oxygen species with severe pathological effects such as bladder cancer in chronic schistosomiasis (<xref ref-type="bibr" rid="B65">65</xref>).</p>
</sec>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Limitations</title>
<p>One of our research goals was to be able to delineate schistosomiasis metabolomic profiles with more emphasis in human specimens. However, five of the identified articles expressly reported metabolic alterations in human biofluids whilst the rest utilised mouse as an animal model although such models are essential in determination of organ or tissue damage due to schisosomiasis. Another limitation was scarcity of relevant literature, arising from inclusion criteria we employed leading to exclusion of other schistosome species such as <italic>S. japonicum</italic>, <italic>S. mekongi</italic>, <italic>S. bovis</italic> and <italic>S. intercalatum</italic> despite that these species are geographically not common in Africa and their global prevalence is very low (<xref ref-type="bibr" rid="B66">66</xref>). Metabolomics studies require robust and expensive equipment such as NMR and HPLC which increases cost of research, this may further contribute to the reason why there is limited literature on metabolomics (<xref ref-type="bibr" rid="B67">67</xref>). Furthermore, the current review could not categorise metabolite alterations based on age groups as most of the studies were skewed towards adults and utilised animal models.</p>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Future perspectives</title>
<p>Metabolomics can contribute immensely in the discovery of biomarkers for diagnostic purposes and in elucidating pathophysiological changes due to schistosome infections. As the race to develop diagnostic and prognosis tools that are highly sensitive and specific continues, metabolomics studies for schistosomiasis are expected to be increasingly carried out (<xref ref-type="bibr" rid="B11">11</xref>). The aspect will contribute to early detection of schistosome infections before the manifestation of severe pathological symptoms and reduces treatment costs by directing MDA programs to populations with high disease prevalence (<xref ref-type="bibr" rid="B68">68</xref>).</p>
<p>For this new field to be positioned in the mainstream of biomarker discovery in infectious diseases specifically schistosomiasis, several issues need to be addressed including validating and reproducing candidate metabolites, methodologies in study design and advanced data analysis. For example, although non-targeted approaches that enable a comprehensive or global analysis to detect novel compounds and generate new hypotheses, the high cost of advanced equipment such as NMR and complex statistical analysis including bioinformatics are required. On the contrary, targeted metabolomics approaches are hypothesis driven, less expensive and require minimum statistical analysis but lack depth in the discovery of unknown metabolites (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B69">69</xref>). Chen and colleagues (<xref ref-type="bibr" rid="B70">70</xref>) revealed that integrating both approaches in study designs maintained some strengths of targeted and untargeted metabolomics analysis, while neutralizing some of their weaknesses thus such holistic approaches should be considered for future studies. Furthermore, such integrative approaches should be extended to study population where all age groups namely pre-school aged children, school aged children and adults are considered in the inclusion criteria for schistosomiasis metabolomics studies as most researches are biased towards individuals above five years (<xref ref-type="bibr" rid="B71">71</xref>).</p>
<p>Despite energy metabolite being significantly altered during <italic>S. haemtobium</italic> and <italic>S. mansoni</italic> infections, gut microbial related compounds hippurate and trimethylamine together with phenylacetylglycine and alanine amino acids were the most promising metabolites for biomarker use. Of much interest was hippurate, which its concentration deviation from normal in metabolomics analysis can be used as an indicator for severity of schistosome infection in addition to diagnostic purposes (<xref ref-type="bibr" rid="B39">39</xref>). However, further analysis such as reproducibility, sensitivity and specificity assays should be done to ascertain the diagnostic accuracy for these biomarkers during schistosomiasis. <xref ref-type="boxed-text" rid="box1">
<bold>Box 1</bold>
</xref> provides a summary of promising metabolite for biomarker use and some of the outstanding questions for the benefit of future metabolomics studies focusing on urogenital and intestinal schistosomiasis.</p>
</sec>
</sec>
<sec id="s4" sec-type="conclusion">
<label>4</label>
<title>Conclusion</title>
<p>Metabolomics is receiving a great deal of attention amongst the omics approaches as it has displayed an immense potential in unearthing novel diagnostic biomarkers and previously unidentified vaccine targets in parasitic infections. This scoping review outlined the current understanding on dysregulation of the metabolic pathway and metabolites can be used as biomarkers in urogenital and intestinal schistosomiasis. A total of 127 metabolites were identified to be altered and energy metabolism was significantly affected, followed by amino acid, gut microbial, structural proteins/lipids, nucleic acid and hormones metabolism. In addition to providing biomarkers for diagnosis and prognosis, the findings of the review provide insight into the complex pathological symptoms and host-parasite relationship during infection. Energy related and structural lipids or proteins metabolite profiles were mainly altered during urogenital schistosomiasis. On the other hand, intestinal schistosomiais largely affected gut-microbial and amino acid metabolic profiles. Although animal models are essential in disease research, the models are often poor predictors of human reactions to infection exposure owing to poor study designs and low replicability of experiments (<xref ref-type="bibr" rid="B72">72</xref>). Most of metabolomics studies identified in this scoping review were animal based studies, therefore there is a need to increase efforts in human studies covering all age groups to complement high numbers in animals related studies thereby enhancing the quality and accuracy of the study and result respectively. Study characteristics revealed that the study population size for metabolomics studies ranges from a 50 to 335 samples with controls for human studies therefore it is evident that it is recommendable to utilise a large sample size to obtain statistically significant results. In contrast, a minimum of 5 mice per control group are deemed sufficient to conduct animal-based metabolomics studies for schistosomiasis. Therefore, we recommend the inclusion of animal models in all human base studies to obtain comparative results. In relation to specimen, most of schistosomiasis metabolomics studies searched for biomarkers in urine due to its simple collection and non-invasiveness which additionally facilitates continuous monitoring of biomarkers as opposed to blood samples which triggers immense pain and psychological trauma especially in paediatrics (<xref ref-type="bibr" rid="B73">73</xref>). Although all analytical platforms were utilised for both untargeted and targeted metabolomics, NMR based and UHPLC methodologies were widely utilised. NMR is relatively less sensitive and very expensive when compared to UHPLC, however its high reproducibility, non-selective nature and the ability to identify unknown metabolites in complex mixtures offer tremendous benefits to the metabolomics field (<xref ref-type="bibr" rid="B74">74</xref>).</p>
<p>Although further research is needed in metabolomics, this overview provides an insight into metabolic perturbations during schistosomiasis infections which is essential in the identification of useful biomarkers and explaining pathologies associated with the disease.</p>
</sec>
<sec id="s5" sec-type="author-contributions">
<title>Author contributions</title>
<p>HM, TM, FM and AV conceived the idea. HM, AV and MK did the literature research, compiled the data and analysed the data. HM and AV wrote the first draft of the manuscript. TM-J, CS, IC and VM gave the suggestions for improvement. TM, FM and TN provided guidance, revised and completed the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="funding-information">
<title>Funding</title>
<p>The proposed study ideation emanated from a study supported by the Royal Society Grants ICA_R1_201399.</p>
</sec>
<sec id="s7" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>Author IC is employed by Aravas Pharmaceuticals Pvt LTD.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<boxed-text id="box1" position="float">
<title>Box 1 Highlights and research gaps for urogenital and intestinal schistosomiasis biomarker discovery using metabolomics techniques</title>
<p>Most promising metabolites</p>
<list list-type="bullet">
<list-item>
<p>
<italic>Energy</italic>: creatine, pyruvate, citrate and aconitate</p>
</list-item>
<list-item>
<p>
<italic>Gut microbial</italic>: hippurate, trimethylamine and p-cresol glucuronide</p>
</list-item>
<list-item>
<p>
<italic>Amino acids</italic>: phenylacetylglycine, alanine, 2-oxoisocaproate benzoic acid and asparagine</p>
</list-item>
<list-item>
<p>
<italic>Immune proteins</italic>: <italic>S. mansoni</italic> phosphoenolpyruvate carboxykinase (SmPEPCK)</p>
</list-item>
</list>
<p>Outstanding research questions</p>
<list list-type="bullet">
<list-item>
<p>What are the differences in metabolite profiles across all age groups during schistosomiasis?</p>
</list-item>
<list-item>
<p>Can current metabolite biomarkers be assessed and validated for diagnostic accuracy in the detection of schistosome infections?</p>
</list-item>
</list>
</boxed-text>
</sec>
<sec id="s8" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s9" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fitd.2023.1108317/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fitd.2023.1108317/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table_1.docx" id="ST1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
<supplementary-material xlink:href="Table_2.xlsx" id="ST2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="Table_3.xlsx" id="ST3" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="Table_4.docx" id="ST4" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Utzinger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Raso</surname> <given-names>G</given-names>
</name>
<name>
<surname>Brooker</surname> <given-names>S</given-names>
</name>
<name>
<surname>De Savigny</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tanner</surname> <given-names>M</given-names>
</name>
<name>
<surname>&#xd8;rnbjerg</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution</article-title>. <source>Parasitology</source> (<year>2009</year>) <volume>136</volume>:<page-range>1859&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/S0031182009991600</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacolo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chimbari</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kalinda</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Knowledge, attitudes and practices on schistosomiasis in sub-Saharan Africa: a systematic review</article-title>. <source>BMC Infect Dis</source> (<year>2018</year>) <volume>18</volume>:<fpage>46</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12879-017-2923-6</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="web">
<source>Schistosomiasis</source> . Available at: <uri xlink:href="https://www.who.int/news-room/fact-sheets/detail/schistosomiasis?:cf_chl_captcha_tk:=pmd_3xnaeLqR14QZD1dclFF2cjTAqI6jQ0fNgzs5GkPJt3A-1634633141-0-gqNtZGzNAxCjcnBszQkR">https://www.who.int/news-room/fact-sheets/detail/schistosomiasis?:cf_chl_captcha_tk:=pmd_3xnaeLqR14QZD1dclFF2cjTAqI6jQ0fNgzs5GkPJt3A-1634633141-0-gqNtZGzNAxCjcnBszQkR</uri> (Accessed <access-date>October 19, 2021</access-date>).</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aula</surname> <given-names>OP</given-names>
</name>
<name>
<surname>McManus</surname> <given-names>DP</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>CA</given-names>
</name>
</person-group>. <article-title>Schistosomiasis with a focus on Africa</article-title>. <source>Trop Med Infect Dis</source> (<year>2021</year>) <volume>6</volume>:<elocation-id>109</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/tropicalmed6030109</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adenowo</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Oyinloye</surname> <given-names>BE</given-names>
</name>
<name>
<surname>Ogunyinka</surname> <given-names>BI</given-names>
</name>
<name>
<surname>Kappo</surname> <given-names>AP</given-names>
</name>
</person-group>. <article-title>Impact of human schistosomiasis in sub-Saharan Africa</article-title>. <source>Braz J Infect Dis</source> (<year>2015</year>) <volume>19</volume>:<fpage>196</fpage>&#x2013;<lpage>205</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bjid.2014.11.004</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Utzinger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Becker</surname> <given-names>SL</given-names>
</name>
<name>
<surname>van Lieshout</surname> <given-names>L</given-names>
</name>
<name>
<surname>van Dam</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Knopp</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>New diagnostic tools in schistosomiasis</article-title>. <source>Clin Microbiol Infect</source> (<year>2015</year>) <volume>21</volume>:<page-range>529&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmi.2015.03.014</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hotez</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Bethony</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Diemert</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Pearson</surname> <given-names>M</given-names>
</name>
<name>
<surname>Loukas</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Developing vaccines to combat hookworm infection and intestinal schistosomiasis</article-title>. <source>Nat Rev Microbiol</source> (<year>2010</year>) <volume>8</volume>:<page-range>814&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrmicro2438</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ajibola</surname> <given-names>O</given-names>
</name>
<name>
<surname>Gulumbe</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Eze</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Obishakin</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Tools for detection of schistosomiasis in resource limited settings</article-title>. <source>Med Sci</source> (<year>2018</year>) <volume>6</volume>(<issue>2</issue>):<fpage>39</fpage>&#x2013;<lpage>54</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/medsci6020039</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osakunor</surname> <given-names>DNM</given-names>
</name>
<name>
<surname>Woolhouse</surname> <given-names>MEJ</given-names>
</name>
<name>
<surname>Mutapi</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Paediatric schistosomiasis: What we know and what we need to know</article-title>. <source>PloS Negl Trop Dis</source> (<year>2018</year>) <volume>12</volume>(<issue>2</issue>):<elocation-id>e0006144&#x2013;57</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0006144</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagan</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sharaf</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>Schistosomiasis vaccines</article-title>. <source>Expert Opin Biol Ther</source> (<year>2003</year>) <volume>3</volume>:<page-range>1271&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1517/14712598.3.8.1271</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preidis</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Hotez</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>The newest &#x201c;Omics&#x201d;&#x2013;metagenomics and metabolomics&#x2013;enter the battle against the neglected tropical diseases</article-title>. <source>PloS Negl Trop Dis</source> (<year>2015</year>) <volume>9</volume>:<fpage>e0003382</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0003382</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wishart</surname> <given-names>DS</given-names>
</name>
</person-group>. <article-title>Applications of metabolomics in drug discovery and development</article-title>. <source>Drugs R D</source> (<year>2008</year>) <volume>9</volume>:<page-range>307&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2165/00126839-200809050-00002</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gowda</surname> <given-names>GAN</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Asiago</surname> <given-names>V</given-names>
</name>
<name>
<surname>Shanaiah</surname> <given-names>N</given-names>
</name>
<name>
<surname>Raftery</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Metabolomics-based methods for early disease diagnostics: A review</article-title>. <source>Expert Rev Mol Diagn</source> (<year>2008</year>) <volume>8</volume>:<elocation-id>617</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1586/14737159.8.5.617</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tokarz</surname> <given-names>J</given-names>
</name>
<name>
<surname>Adamski</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lani&#x161;nik Ri&#x17e;ner</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Metabolomics for diagnosis and prognosis of uterine diseases? a systematic review</article-title>. <source>J Pers Med</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>294</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/jpm10040294</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>A</given-names>
</name>
<name>
<surname>Miao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>H</given-names>
</name>
<name>
<surname>Han</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolomics biotechnology, applications, and future trends: a systematic review</article-title>. <source>RSC Adv</source> (<year>2019</year>) <volume>9</volume>:<page-range>37245&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/C9RA06697G</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tounta</surname> <given-names>V</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cheyne</surname> <given-names>A</given-names>
</name>
<name>
<surname>Larrouy-Maumus</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Metabolomics in infectious diseases and drug discovery</article-title>. <source>Mol Omics</source> (<year>2021</year>) <volume>17</volume>:<page-range>376&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/D1MO00017A</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inobaya</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Olveda</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Chau</surname> <given-names>TN</given-names>
</name>
<name>
<surname>Olveda</surname> <given-names>DU</given-names>
</name>
<name>
<surname>Ross</surname> <given-names>AG</given-names>
</name>
</person-group>. <article-title>Prevention and control of schistosomiasis: a current perspective</article-title>. <source>Res Rep Trop Med</source> (<year>2014</year>) <volume>5</volume>:<fpage>65</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/RRTM.S44274</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krauth</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Balen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gobert</surname> <given-names>GN</given-names>
</name>
<name>
<surname>Lamberton</surname> <given-names>PHL</given-names>
</name>
</person-group>. <article-title>A call for systems epidemiology to tackle the complexity of schistosomiasis, its control, and its elimination</article-title>. <source>Trop Med Infect Dis</source> (<year>2019</year>) <volume>4</volume>:<elocation-id>21</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/tropicalmed4010021</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>L-P</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zuo</surname> <given-names>Y-P</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>Q-B</given-names>
</name>
<name>
<surname>Du</surname> <given-names>G-L</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y-C</given-names>
</name>
<etal/>
</person-group>. <article-title>A multidisciplinary, integrated approach for the elimination of schistosomiasis: a longitudinal study in a historically hyper-endemic region in the lower reaches of the Yangtze river, China from 2005 to 2014</article-title>. <source>Infect Dis Poverty</source> (<year>2017</year>) <volume>6</volume>:<fpage>56</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40249-017-0270-x</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weerakoon</surname> <given-names>KGAD</given-names>
</name>
<name>
<surname>Gobert</surname> <given-names>GN</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>P</given-names>
</name>
<name>
<surname>McManus</surname> <given-names>DP</given-names>
</name>
</person-group>. <article-title>Advances in the diagnosis of human schistosomiasis</article-title>. <source>Clin Microbiol Rev</source> (<year>2015</year>) <volume>28</volume>:<page-range>939&#x2013;67</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/CMR.00137-14</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adebayo</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Mundhe</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Awobode</surname> <given-names>HO</given-names>
</name>
<name>
<surname>Onile</surname> <given-names>OS</given-names>
</name>
<name>
<surname>Agunloye</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Isokpehi</surname> <given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolite profiling for biomarkers in schistosoma haematobium infection and associated bladder pathologies</article-title>. <source>PloS Negl Trop Dis</source> (<year>2018</year>) <volume>12</volume>:<fpage>e0006452</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0006452</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergquist</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mv J</surname> <given-names>JU</given-names>
</name>
</person-group>. <article-title>Diagnostic dilemmas in helminthology: what tools to use and when</article-title>? <source>Trends Parasitol</source> (<year>2009</year>) <volume>25</volume>(<issue>4</issue>):<page-range>151&#x2013;156</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pt.2009.01.004</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiff</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Accurate diagnostics for schistosomiasis: a new role for PCR</article-title>? <source>RIP</source> (<year>2015</year>) <volume>4</volume>:<page-range>23&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/RIP.S74319</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alarcon-Barrera</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Kostidis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ondo-Mendez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Giera</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Recent advances in metabolomics analysis for early drug development</article-title>. <source>Drug Discovery Today</source> (<year>2022</year>) <volume>27</volume>:<page-range>1763&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.drudis.2022.02.018</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arksey</surname> <given-names>H</given-names>
</name>
<name>
<surname>O&#x2019;Malley</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Scoping studies: towards a methodological framework</article-title>. <source>Int J Soc Res Method</source> (<year>2005</year>) <volume>8</volume>:<fpage>19</fpage>&#x2013;<lpage>32</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/1364557032000119616</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tricco</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Lillie</surname> <given-names>E</given-names>
</name>
<name>
<surname>Zarin</surname> <given-names>W</given-names>
</name>
<name>
<surname>O&#x2019;Brien</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Colquhoun</surname> <given-names>H</given-names>
</name>
<name>
<surname>Levac</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation</article-title>. <source>Ann Intern Med</source> (<year>2018</year>) <volume>169</volume>:<page-range>467&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7326/M18-0850</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munn</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Peters</surname> <given-names>MDJ</given-names>
</name>
<name>
<surname>Stern</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tufanaru</surname> <given-names>C</given-names>
</name>
<name>
<surname>McArthur</surname> <given-names>A</given-names>
</name>
<name>
<surname>Aromataris</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Systematic review or scoping review? guidance for authors when choosing between a systematic or scoping review approach</article-title>. <source>BMC Med Res Methodol</source> (<year>2018</year>) <volume>18</volume>:<fpage>143</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12874-018-0611-x</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brien</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Lorenzetti</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Lewis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kennedy</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ghali</surname> <given-names>WA</given-names>
</name>
</person-group>. <article-title>Overview of a formal scoping review on health system report cards</article-title>. <source>Implement Sci</source> (<year>2010</year>) <volume>5</volume>:<elocation-id>2</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1748-5908-5-2</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Holmes</surname> <given-names>E</given-names>
</name>
<name>
<surname>Nicholson</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Cloarec</surname> <given-names>O</given-names>
</name>
<name>
<surname>Chollet</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tanner</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabonomic investigations in mice infected with schistosoma mansoni: an approach for biomarker identification</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2004</year>) <volume>101</volume>:<page-range>12676&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0404878101</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Perez</surname> <given-names>I</given-names>
</name>
<name>
<surname>Angulo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Utzinger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Holmes</surname> <given-names>E</given-names>
</name>
<name>
<surname>Legido-Quigley</surname> <given-names>C</given-names>
</name>
<name>
<surname>Barbas</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Chemometric and biological validation of a capillary electrophoresis metabolomic experiment of schistosoma mansoni infection in mice</article-title>. <source>Electrophoresis</source> (<year>2010</year>) <volume>31</volume>:<page-range>2338&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/elps.200900523</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>JV</given-names>
</name>
<name>
<surname>Holmes</surname> <given-names>E</given-names>
</name>
<name>
<surname>Saric</surname> <given-names>J</given-names>
</name>
<name>
<surname>Keiser</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dirnhofer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Utzinger</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolic profiling of a schistosoma mansoni infection in mouse tissues using magic angle spinning-nuclear magnetic resonance spectroscopy</article-title>. <source>Int J Parasitol</source> (<year>2009</year>) <volume>39</volume>:<page-range>547&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijpara.2008.10.010</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manivannan</surname> <given-names>B</given-names>
</name>
<name>
<surname>Jordan</surname> <given-names>TW</given-names>
</name>
<name>
<surname>Secor</surname> <given-names>WE</given-names>
</name>
<name>
<surname>La Flamme</surname> <given-names>AC</given-names>
</name>
</person-group>. <article-title>Proteomic changes at 8 weeks after infection are associated with chronic liver pathology in experimental schistosomiasis</article-title>. <source>J Proteomics</source> (<year>2012</year>) <volume>75</volume>:<page-range>1838&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jprot.2011.12.025</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>JV</given-names>
</name>
<name>
<surname>Saric</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Keiser</surname> <given-names>J</given-names>
</name>
<name>
<surname>Utzinger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Holmes</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Chemometric analysis of biofluids from mice experimentally infected with schistosoma mansoni</article-title>. <source>Parasit Vectors</source> (<year>2011</year>) <volume>4</volume>:<elocation-id>179</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1756-3305-4-179</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balog</surname> <given-names>CIA</given-names>
</name>
<name>
<surname>Meissner</surname> <given-names>A</given-names>
</name>
<name>
<surname>G&#xf6;raler</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bladergroen</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Vennervald</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Mayboroda</surname> <given-names>OA</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabonomic investigation of human schistosoma mansoni infection</article-title>. <source>Mol Biosyst</source> (<year>2011</year>) <volume>7</volume>:<page-range>1473&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/C0MB00262C</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manivannan</surname> <given-names>B</given-names>
</name>
<name>
<surname>Rawson</surname> <given-names>P</given-names>
</name>
<name>
<surname>Jordan</surname> <given-names>TW</given-names>
</name>
<name>
<surname>Karanja</surname> <given-names>DMS</given-names>
</name>
<name>
<surname>Mwinzi</surname> <given-names>PNM</given-names>
</name>
<name>
<surname>Secor</surname> <given-names>WE</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of cytokeratin 18 as a biomarker of mouse and human hepatosplenic schistosomiasis</article-title>. <source>Infect Immun</source> (<year>2011</year>) <volume>79</volume>:<page-range>2051&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.01214-10</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onile</surname> <given-names>OS</given-names>
</name>
<name>
<surname>Calder</surname> <given-names>B</given-names>
</name>
<name>
<surname>Soares</surname> <given-names>NC</given-names>
</name>
<name>
<surname>Anumudu</surname> <given-names>CI</given-names>
</name>
<name>
<surname>Blackburn</surname> <given-names>JM</given-names>
</name>
</person-group>. <article-title>Quantitative label-free proteomic analysis of human urine to identify novel candidate protein biomarkers for schistosomiasis</article-title>. <source>PloS Negl Trop Dis</source> (<year>2017</year>) <volume>11</volume>:<fpage>e0006045</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0006045</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osakunor</surname> <given-names>DNM</given-names>
</name>
<name>
<surname>Mduluza</surname> <given-names>T</given-names>
</name>
<name>
<surname>Osei-Hyiaman</surname> <given-names>D</given-names>
</name>
<name>
<surname>Burgess</surname> <given-names>K</given-names>
</name>
<name>
<surname>Woolhouse</surname> <given-names>MEJ</given-names>
</name>
<name>
<surname>Mutapi</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Schistosoma haematobium infection is associated with alterations in energy and purine-related metabolism in preschool-aged children</article-title>. <source>PloS Negl Trop Dis</source> (<year>2020</year>) <volume>14</volume>:<fpage>e0008866</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0008866</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bexkens</surname> <given-names>ML</given-names>
</name>
<name>
<surname>van Gestel</surname> <given-names>RA</given-names>
</name>
<name>
<surname>van Breukelen</surname> <given-names>B</given-names>
</name>
<name>
<surname>Urbanus</surname> <given-names>RT</given-names>
</name>
<name>
<surname>Brouwers</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Nieuwland</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Schistosoma mansoni infection affects the proteome and lipidome of circulating extracellular vesicles in the host</article-title>. <source>Mol Biochem Parasitol</source> (<year>2020</year>) <volume>238</volume>:<elocation-id>111296</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molbiopara.2020.111296</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loyo</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Zarate</surname> <given-names>E</given-names>
</name>
<name>
<surname>Barbosa</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Simoes-Barbosa</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Gas chromatography-mass spectrometry (GC/MS) reveals urine metabolites associated to light and heavy infections by schistosoma mansoni in mice</article-title>. <source>Parasitol Int</source> (<year>2021</year>) <volume>80</volume>:<elocation-id>102239</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.parint.2020.102239</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bueding</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Carbohydrate metabolism of schistosoma mansoni</article-title>. <source>J Gen Physiol</source> (<year>1950</year>) <volume>33</volume>:<page-range>475&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1085/jgp.33.5.475</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rigoulet</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bouchez</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Paumard</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ransac</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cuvellier</surname> <given-names>S</given-names>
</name>
<name>
<surname>Duvezin-Caubet</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Cell energy metabolism: An update</article-title>. <source>Biochim Biophys Acta Bioenerg</source> (<year>2020</year>) <volume>1861</volume>:<elocation-id>148276</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbabio.2020.148276</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tielens</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Celik</surname> <given-names>C</given-names>
</name>
<name>
<surname>Van den Heuvel</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Elfring</surname> <given-names>RH</given-names>
</name>
<name>
<surname>Van den Bergh</surname> <given-names>SG</given-names>
</name>
</person-group>. <article-title>Synthesis and degradation of glycogen by schistosoma mansoni worms in vitro</article-title>. <source>Parasitology</source> (<year>1989</year>) <volume>98</volume>(<issue>Pt 1</issue>):<fpage>67</fpage>&#x2013;<lpage>73</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/s0031182000059692</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yarian</surname> <given-names>C</given-names>
</name>
<name>
<surname>Toroser</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sohal</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Aconitase is the main functional target of aging in the citric acid cycle of kidney mitochondria from mice</article-title>. <source>Mech Ageing Dev</source> (<year>2006</year>) <volume>127</volume>:<fpage>79</fpage>&#x2013;<lpage>84</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mad.2005.09.028</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osakunor</surname> <given-names>DNM</given-names>
</name>
<name>
<surname>Munk</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mduluza</surname> <given-names>T</given-names>
</name>
<name>
<surname>Petersen</surname> <given-names>TN</given-names>
</name>
<name>
<surname>Brinch</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ivens</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The gut microbiome but not the resistome is associated with urogenital schistosomiasis in preschool-aged children</article-title>. <source>Commun Biol</source> (<year>2020</year>) <volume>3</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s42003-020-0859-7</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delaney</surname> <given-names>J</given-names>
</name>
<name>
<surname>Neville</surname> <given-names>WA</given-names>
</name>
<name>
<surname>Swain</surname> <given-names>A</given-names>
</name>
<name>
<surname>Miles</surname> <given-names>A</given-names>
</name>
<name>
<surname>Leonard</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Waterfield</surname> <given-names>CJ</given-names>
</name>
</person-group>. <article-title>Phenylacetylglycine, a putative biomarker of phospholipidosis: Its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model</article-title>. <source>Biomarkers</source> (<year>2008</year>) <volume>9</volume>(<issue>3</issue>):<page-range>271&#x2013;290</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/13547500400018570</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vennervald</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Dunne</surname> <given-names>DW</given-names>
</name>
</person-group>. <article-title>Chronic hepatosplenomegaly in African school children: A common but neglected morbidity associated with schistosomiasis and malaria</article-title>. <source>PloS Negl Trop Dis</source> (<year>2011</year>) <volume>5</volume>:<fpage>e1149</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0001149</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname> <given-names>H</given-names>
</name>
<name>
<surname>Stephenson</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Gobert</surname> <given-names>GN</given-names>
</name>
<name>
<surname>McManus</surname> <given-names>DP</given-names>
</name>
</person-group>. <article-title>Revisiting glucose uptake and metabolism in schistosomes: new molecular insights for improved schistosomiasis therapies</article-title>. <source>Front Genet</source> (<year>2014</year>) <volume>5</volume>:<elocation-id>176</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2014.00176</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senussi</surname> <given-names>NH</given-names>
</name>
<name>
<surname>Manne</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Persistently elevated liver enzymes caused by schistosoma mansoni</article-title>. <source>Clin Gastroenterol Hepatol</source> (<year>2022</year>) <volume>20</volume>:<fpage>A18</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cgh.2020.08.050</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanabe</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kaneko</surname> <given-names>N</given-names>
</name>
<name>
<surname>Takeuchi</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Schistosoma mansoni: Higher free proline levels in the livers of infected mice</article-title>. <source>Exp Parasitol</source> (<year>1991</year>) <volume>72</volume>:<page-range>134&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0014-4894(91)90131-F</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y-R</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ni</surname> <given-names>X-Q</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>J-L</given-names>
</name>
<etal/>
</person-group>. <article-title>Taurine alleviates schistosoma-induced liver injury by inhibiting the TXNIP/NLRP3 inflammasome signal pathway and pyroptosis</article-title>. <source>Infection Immun</source> (<year>2019</year>) <volume>87</volume>:<page-range>e00732&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.00732-19</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzpatrick</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Fuentes</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Chalmers</surname> <given-names>IW</given-names>
</name>
<name>
<surname>Wynn</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Modolell</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hoffmann</surname> <given-names>KF</given-names>
</name>
<etal/>
</person-group>. <article-title>Schistosoma mansoni arginase shares functional similarities with human orthologs but depends upon disulphide bridges for enzymatic activity</article-title>. <source>Int J Parasitol</source> (<year>2009</year>) <volume>39</volume>:<page-range>267&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijpara.2008.06.015</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asahi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Osman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cook</surname> <given-names>RM</given-names>
</name>
<name>
<surname>LoVerde</surname> <given-names>PT</given-names>
</name>
<name>
<surname>Stadecker</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>Schistosoma mansoni phosphoenolpyruvate carboxykinase, a novel egg antigen: immunological properties of the recombinant protein and identification of a T-cell epitope</article-title>. <source>Infect Immun</source> (<year>2000</year>) <volume>68</volume>:<page-range>3385&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.68.6.3385-3393.2000</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colley</surname> <given-names>DG</given-names>
</name>
<name>
<surname>Secor</surname> <given-names>WE</given-names>
</name>
</person-group>. <article-title>Immunology of human schistosomiasis</article-title>. <source>Parasite Immunol</source> (<year>2014</year>) <volume>36</volume>:<page-range>347&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pim.12087</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubovsky</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Chappell</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Harrington</surname> <given-names>BK</given-names>
</name>
<name>
<surname>Agrawal</surname> <given-names>K</given-names>
</name>
<name>
<surname>Andritsos</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Flynn</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing</article-title>. <source>Blood</source> (<year>2013</year>) <volume>122</volume>:<page-range>3308&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2013-05-504597</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>W-J</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>M-J</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y-D</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>Q-P</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>H-F</given-names>
</name>
<etal/>
</person-group>. <article-title>Prohibitin 1 (PHB1) controls growth and development and regulates proliferation and apoptosis in schistosoma japonicum</article-title>. <source>FASEB J</source> (<year>2020</year>) <volume>34</volume>:<page-range>11030&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1096/fj.201902787RRR</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieczorek</surname> <given-names>M</given-names>
</name>
<name>
<surname>Abualrous</surname> <given-names>ET</given-names>
</name>
<name>
<surname>Sticht</surname> <given-names>J</given-names>
</name>
<name>
<surname>&#xc1;lvaro-Benito</surname> <given-names>M</given-names>
</name>
<name>
<surname>Stolzenberg</surname> <given-names>S</given-names>
</name>
<name>
<surname>No&#xe9;</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Major histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>292</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00292</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meurs</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mbow</surname> <given-names>M</given-names>
</name>
<name>
<surname>Boon</surname> <given-names>N</given-names>
</name>
<name>
<surname>Vereecken</surname> <given-names>K</given-names>
</name>
<name>
<surname>Amoah</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Labuda</surname> <given-names>LA</given-names>
</name>
<etal/>
</person-group>. <article-title>Cytokine responses to schistosoma mansoni and schistosoma haematobium in relation to infection in a Co-endemic focus in northern Senegal</article-title>. <source>PloS Negl Trop Dis</source> (<year>2014</year>) <volume>8</volume>:<fpage>e3080</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0003080</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chalmers</surname> <given-names>IW</given-names>
</name>
<name>
<surname>Hoffmann</surname> <given-names>KF</given-names>
</name>
</person-group>. <article-title>Platyhelminth venom allergen-like (VAL) proteins: revealing structural diversity, class-specific features and biological associations across the phylum</article-title>. <source>Parasitology</source> (<year>2012</year>) <volume>139</volume>:<page-range>1231&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/S0031182012000704</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iruela-Arispe</surname> <given-names>ML</given-names>
</name>
</person-group>. <article-title>Membrane lipids and cell signaling</article-title>. <source>Curr Opin Lipidol</source> (<year>2017</year>) <volume>28</volume>:<page-range>408&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MOL.0000000000000443</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito R de</surname> <given-names>F</given-names>
</name>
<name>
<surname>Andrade LN de</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bustos</surname> <given-names>SO</given-names>
</name>
<name>
<surname>Chammas</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Phosphatidylcholine-derived lipid mediators: The crosstalk between cancer cells and immune cells</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>768606</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.768606</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bhujwalla</surname> <given-names>ZM</given-names>
</name>
<name>
<surname>Glunde</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Targeting phospholipid metabolism in cancer</article-title>. <source>Front Oncol</source> (<year>2016</year>) <volume>6</volume>:<elocation-id>266</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2016.00266</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szlasa</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zendran</surname> <given-names>I</given-names>
</name>
<name>
<surname>Zalesi&#x144;ska</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tarek</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kulbacka</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Lipid composition of the cancer cell membrane</article-title>. <source>J Bioenerg Biomembr</source> (<year>2020</year>) <volume>52</volume>:<page-range>321&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10863-020-09846-4</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Botelho</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Alves</surname> <given-names>H</given-names>
</name>
<name>
<surname>Richter</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Estrogen catechols detection as biomarkers in schistosomiasis induced cancer and infertility</article-title>. <source>Lett Drug Des Discovery</source> (<year>2017</year>) <volume>14</volume>:<page-range>135&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.2174/1570180813666160720165057</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Correia da Costa</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Vale</surname> <given-names>N</given-names>
</name>
<name>
<surname>Gouveia</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Botelho</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Sripa</surname> <given-names>B</given-names>
</name>
<name>
<surname>Santos</surname> <given-names>LL</given-names>
</name>
<etal/>
</person-group>. <article-title>Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers</article-title>. <source>Front Genet</source> (<year>2014</year>) <volume>5</volume>:<elocation-id>444</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2014.00444</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baez</surname> <given-names>S</given-names>
</name>
<name>
<surname>Segura-Aguilar</surname> <given-names>J</given-names>
</name>
<name>
<surname>Widersten</surname> <given-names>M</given-names>
</name>
<name>
<surname>Johansson</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Mannervik</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes</article-title>. <source>Biochem J</source> (<year>1997</year>) <volume>324</volume>(<issue>Pt 1</issue>):<page-range>25&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/bj3240025</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chitsulo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Engels</surname> <given-names>D</given-names>
</name>
<name>
<surname>Montresor</surname> <given-names>A</given-names>
</name>
<name>
<surname>Savioli</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>The global status of schistosomiasis and its control</article-title>. <source>Acta Trop</source> (<year>2000</year>) <volume>77</volume>:<fpage>41</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0001-706X(00)00122-4</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lokhov</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Trifonova</surname> <given-names>OP</given-names>
</name>
<name>
<surname>Maslov</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Lichtenberg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Balashova</surname> <given-names>EE</given-names>
</name>
</person-group>. <article-title>Personal metabolomics: A global challenge</article-title>. <source>Metabolites</source> (<year>2021</year>) <volume>11</volume>(<issue>11</issue>):<elocation-id>715</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/metabo11110715</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Secor</surname> <given-names>WE</given-names>
</name>
</person-group>. <article-title>Early lessons from schistosomiasis mass drug administration programs</article-title>. <source>F1000Res</source> (<year>2015</year>) <volume>4</volume>:<page-range>F1000 Faculty Rev&#x2013;1157</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.12688/f1000research.6826.1</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Gonzalez</surname> <given-names>FJ</given-names>
</name>
</person-group>. <article-title>Challenges and opportunities of metabolomics</article-title>. <source>J Cell Physiol</source> (<year>2012</year>) <volume>227</volume>:<page-range>2975&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcp.24002</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Bridging targeted and untargeted mass spectrometry-based metabolomics <italic>via</italic> hybrid approaches</article-title>. <source>Metabolites</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>348</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/metabo10090348</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mduluza</surname> <given-names>T</given-names>
</name>
<name>
<surname>Mutapi</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Putting the treatment of paediatric schistosomiasis into context</article-title>. <source>Infect Dis Poverty</source> (<year>2017</year>) <volume>6</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40249-017-0300-8</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bracken</surname> <given-names>MB</given-names>
</name>
</person-group>. <article-title>Why animal studies are often poor predictors of human reactions to exposure</article-title>. <source>J R Soc Med</source> (<year>2009</year>) <volume>102</volume>:<page-range>120&#x2013;2</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1258/jrsm.2008.08k033</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ialongo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bernardini</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Phlebotomy, a bridge between laboratory and patient</article-title>. <source>Biochem Med (Zagreb)</source> (<year>2016</year>) <volume>26</volume>:<fpage>17</fpage>&#x2013;<lpage>33</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.11613/BM.2016.002</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gowda</surname> <given-names>GAN</given-names>
</name>
<name>
<surname>Raftery</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>NMR based metabolomics</article-title>. <source>Adv Exp Med Biol</source> (<year>2021</year>) <volume>1280</volume>:<fpage>19</fpage>&#x2013;<lpage>37</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-030-51652-9_2</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>